Open AccessOutcomes of Chemotherapy for Microsatellite Instable–High Metastatic Colorectal Cancers
Author(s) -
Katerina Shulman,
Ofra BarnettGriness,
Vered Friedman,
Joel K. Greenson,
Stephen B. Gruber,
Flavio Lejbkowicz,
Gad Rennert
Publication year - 2018
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.17.00253
Subject(s) - medicine , bevacizumab , colorectal cancer , oncology , hazard ratio , microsatellite instability , chemotherapy , population , cancer , gastroenterology , microsatellite , allele , biology , confidence interval , biochemistry , environmental health , gene
Microsatellite instable-high (MSI-H) colorectal cancers (CRCs) are known to carry better survival in the local disease stage even without treatment. The influence of types of treatment on survival of MSI-H metastatic CRCs (mCRCs) is still unclear and is evaluated in this study.